Glyscend Therapeutics Announces Publication of GLY-200 First-in-Human Data and Availability of Phase 2a Clinical Results

B oston, MA (July 27, 2023) – Glyscend Therapeutics… today announced that safety and pharmacodynamic data from the first-in-human Phase 1 trial of GLY-200 were published in Diabetes, Obesity and Metabolism . The data published demonstrate that GLY-200, the company’s lead clinical candidate, mimics the biomarker signature seen with metabolic surgery and appeared to be safe and generally well-tolerated. LEARN MORE

The release as fetched from its publisher. glyscend.com ↗